Lenvatinib as a single agent and is available in the whole of the UK. Lenvatinib is indicated 'in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted...
Kidney Cancer UK have collated information about the current drug based treatment options.
Pembrolizumab (Keytruda) is a type of immunotherapy. It stimulates the body’s immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find...
A special blog for Kidney Cancer Awareness Week 2023 by Richard Jetten I was 41 and running our own Spanish Tapas restaurant when one morning I noticed my wee had turned red, it looked just like Cherryade! Initially I dismissed this as a bad bottle of red wine from...
Everolimus (Afinitor) is an active inhibitor of the mammalian target of rapamycin (mTOR) protein, a central regulator of tumour cell division and blood vessel growth in cancer cells. It is given in tablet form and can be given as a single medication or in combination...
The drug duo Kisplyx plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed. Kisplyx (lenvatinib) plus Keytruda (pembrolizumab) improved outcomes in patients with advanced renal cell...
Lessons learned Hello everyone, my name is Scott. I’m in my late 50s and have been living with Stage 4 kidney cancer (clear cell renal cell carcinoma – ccRCC) since 2019. Unfortunately, it took almost a year to...
I’m Kevin. I’m 67, and I never imagined my life would change so suddenly, or so dramatically. My cancer journey began with symptoms that were impossible to ignore. Persistent night sweats, then sudden, severe pain on the right side of my abdomen, followed by a...
